Orthocell proudly congratulates our Co-Founder and Chief Scientific Officer, Professor Minghao Zheng AM, on being appointed a Member of the Order of Australia (AM).
The AFR has profiled Orthocell’s increased investment in Marine Biomedical and its novel bone-repair technology, PearlBone™, in this article by Tom Rabe titled ‘The company repairing human bone with Kimberley pearl shells.’ Orthocell Chairman John Van Der Wielen explains that this investment contributes to Orthocell’s broader strategy to support surgeons with a more complete trauma-repair toolkit spanning nerve, tendon and bone, while bringing new […]
Orthocell has today released its Quarterly Report for the period ended 31 December 2025 – a quarter marked by continued revenue growth and accelerating U.S. commercialisation.
Orthocell has entered into a binding Formal Agreement with Marine Biomedical, increasing its equity interest from 1.72% to 11.7% for a total investment of AU$1.05 million. As part of the transaction, Orthocell has secured a first right of refusal over global distribution rights for PearlBone™, Marine Biomedical’s bone regeneration technology, and any future bone repair and regeneration products. PearlBone is an […]
Orthocell Chairman John Van Der Wielen recently spoke with ausbiz about the Company’s strategic investment in Marine Biomedical and the rationale behind securing global distribution rights to PearlBone™.
For the quarter ended 31 December 2025, the Company achieved record quarterly revenue of $3.2 million, representing a 7.0% increase on the prior quarterly record and a 45.2% increase on the prior corresponding period. This outcome reflects a compound quarterly growth rate of 10.4% since Q3 FY24.
Orthocell has submitted a regulatory application to the British Standards Institution (BSI) seeking approval to commercially distribute Remplir™ in the European Union and United Kingdom, a combined nerve repair market valued at approximately US$750 million and comprising an estimated 500,000 peripheral nerve repair procedures each year.
Orthocell has announced that it has completed the first commercial sales of Remplir™ in Hong Kong, representing a key milestone in the Company’s Asian growth strategy.
Momentum is growing for Remplir™ in nerve-sparing prostate cancer surgery, with around 100 surgeries now performed using the flagship nerve repair device.
Orthocell has appointed its second distributor in Canada. The appointment completes national coverage across the US$75 million Canadian market, ensuring access for patients and healthcare providers nationwide.